title: Variability in 4-hydroperoxycyclophosphamide activity during clinical purging for autologous bone marrow transplantation.
abstract: We examined the effects of varying incubation conditions on the in vitro activity of 4-hydroperoxycyclophosphamide (4HC). 4HC activity against CFU-GM and against the K562 tumor cell line decreased with increasing the RBC concentration of the incubation mixture. Increasing the concentration of nucleated bone marrow cells in the incubation mixture also decreased the 4HC activity. Evaluation of 53 consecutive patients undergoing autologous bone marrow transplantation (BMT) revealed that the incubation RBC concentration during clinical purging showed a similar effect on CFU-GM recovery. Aldehyde dehydrogenase content of RBCs and nucleated marrow cells appears to be the cause of the inhibition of 4HC activity. Although there was no difference in individual CFU-GM sensitivity to 4HC among normals, previously treated patients undergoing autologous BMT showed significant variability in CFU-GM sensitivity to 4HC. The combined effects of incubation RBC concentration and individual patient 4HC sensitivity appear to account for most of the variability in CFU-GM recovery and speed of hematologic recovery after clinical purging with 4HC.
authors.affiliation: Johns Hopkins Oncology Center, Johns Hopkins Medical Institutions, Baltimore, MD 21205.
authors.forename: R J
authors.initials: RJ
authors.lastname: Jones
authors.forename: M
authors.initials: M
authors.lastname: Zuehlsdorf
authors.forename: S D
authors.initials: SD
authors.lastname: Rowley
authors.forename: J
authors.initials: J
authors.lastname: Hilton
authors.forename: G W
authors.initials: GW
authors.lastname: Santos
authors.forename: L L
authors.initials: LL
authors.lastname: Sensenbrenner
authors.forename: O M
authors.initials: OM
authors.lastname: Colvin
mesh_terms: D001853:Bone Marrow / Q000473:pathology; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D003114:Colony-Forming Units Assay; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004912:Erythrocytes / Q000166:cytology / Q000187:drug effects; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D014182:Transplantation, Autologous
chemical_list: D003520:Cyclophosphamide; C011272:perfosfamide